Benjamin J Solomon
Overview
Explore the profile of Benjamin J Solomon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
11561
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Robledo K, Lefresne S, Soon Y, Sahgal A, Pinkham M, Nichol A, et al.
BMJ Open
. 2024 Jul;
14(7):e078335.
PMID: 38969367
Background: Patients with advanced non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor () gene are a heterogeneous population who often develop brain metastases (BM). The...
12.
Spicer J, Cascone T, Wynes M, Ahn M, Dacic S, Felip E, et al.
J Thorac Oncol
. 2024 Jun;
19(10):1373-1414.
PMID: 38901648
Advances in the multidisciplinary care of early stage resectable NSCLC (rNSCLC) are emerging at an unprecedented pace. Numerous phase 3 trials produced results that have transformed patient outcomes for the...
13.
Perol M, Solomon B, Goto K, Park K, Nadal E, Bria E, et al.
J Clin Oncol
. 2024 Jun;
42(21):2500-2505.
PMID: 38828957
JCO .Although the CNS activity of selpercatinib in patients with fusion-positive non-small cell lung cancer (NSCLC) has been previously described, the ability of potent RET inhibition to prevent new CNS...
14.
Solomon B, Liu G, Felip E, Mok T, Soo R, Mazieres J, et al.
J Clin Oncol
. 2024 May;
42(29):3400-3409.
PMID: 38819031
Purpose: Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, -positive non-small cell lung cancer (NSCLC) in the phase III CROWN study. Here,...
15.
Armstrong A, Geva R, Chung H, Lemech C, Miller Jr W, Hansen A, et al.
Invest New Drugs
. 2024 May;
42(3):340-341.
PMID: 38767685
No abstract available.
16.
McLean L, Lim A, Angel C, Young R, Pizzolla A, Archer S, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672534
Non-melanomatous cutaneous spindle cell neoplasms are a rare group of malignancies that present a diagnostic challenge, and for which there is a lack of consensus on how to best manage...
17.
Chan J, Scheffler C, Munoz I, Sek K, Lee J, Huang Y, et al.
Nature
. 2024 Apr;
629(8010):201-210.
PMID: 38600376
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of haematological malignancies such as acute lymphoblastic leukaemia, B cell lymphoma and multiple myeloma, but the efficacy of CAR...
18.
Wu Y, Dziadziuszko R, Ahn J, Barlesi F, Nishio M, Lee D, et al.
N Engl J Med
. 2024 Apr;
390(14):1265-1276.
PMID: 38598794
Background: Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, -positive non-small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectinib as compared with chemotherapy...
19.
Liu G, Mazieres J, Stratmann J, Ou S, Mok T, Grizzard M, et al.
Lung Cancer
. 2024 Mar;
191:107535.
PMID: 38554546
Lorlatinib is a brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). In clinical trials, lorlatinib has shown...
20.
Tan L, Brown C, Mersiades A, Lee C, John T, Kao S, et al.
Nat Commun
. 2024 Feb;
15(1):1823.
PMID: 38418463
In this phase II, single arm trial (ACTRN12617000720314), we investigate if alternating osimertinib and gefitinib would delay the development of resistance to osimertinib in advanced, non-small cell lung cancer (NSCLC)...